Arvinas vp David Loomis sells $1,475 in stock
At a glance
- $ARVN today−0.73%last $6.77
- Vs industry peers−0.34 pts6-peer median −0.39% · in step
- Since Nov 9+1.65%from the first trade after the story
- 52-week range7.0% above low$6.33 – $14.51
- Cash runway~6 mo$88.0M cash ÷ $14.3M/mo burn · 10-Q
- In the headline$1,475Amount
Nothing reported about arvinas across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: The headline zeroes in on $1,475 — a single number, but it's the tip of a much larger iceberg. Context matters, and the trend behind it tells the real story.
- How the stock is trading: $ARVN -0.73% in the latest session.
- Timing: It came out after the closing bell. The session change shown was settled before the story existed, and the next session is the first that could react.
Where the stock stands
Arvinas ($ARVN) slipped 0.73% to $6.77 in the latest session. Over the past month it is down 6.7%. That leaves it 53% below its 52-week high of $14.51 and 7.0% above its low of $6.33, close to the bottom of its range. The year's high was 2.3 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 3, 2026), $ARVN lost $53.9M over the quarter to Sep 30, 2026 on revenue of $500K (-99.8% QoQ). Operations used $127.9M of cash over the nine months to Sep 30, 2026 — about $14.3M a month — against $88.0M in cash on Sep 30, 2026. At that pace the cash covers about 6 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. It carried $400K of debt against $88.0M of cash on Sep 30, 2026 — net cash of $87.6M. Its most recent filings before this story: 10-Q on Nov 3, 2026, 8-K on Nov 3, 2026, 10-Q on Aug 4, 2026. Figures are as filed with the SEC; the $ARVN page has the full statements.
How much coverage it is getting
Wook has no other story on Arvinas from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
In healthcare, timing is everything — trial results, FDA rulings, and pricing shifts can send stocks soaring or sinking. One event can shift a drugmaker's fate, while a policy change can ripple across the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $ARVN page has the full chart, filings, and valuation models. Since one outlet dominates the coverage, checking another is the fastest way to see if the story is confirmed or just repeated. And Wook AI is here to help with the math — how far $ARVN has come, or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 9, 2026. $ARVN has moved +1.65% ($6.66 to $6.77). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
